Dechra Purchases Veterinary Insulin Programs from Akston Biosciences

Dechra Limited, a global specialist veterinary pharmaceuticals and related products business, and Akston Biosciences Corporation, dedicated to accelerating the biologics revolution in Animal Health, today announces Dechra’s purchase of all Akston’s interests in the companies’ dog and cat long-acting insulin programs. Dechra’s purchase gives it ownership of the intellectual property and rights for the development, manufacturing, and worldwide commercialization of both programs. For its interests, Akston receives an upfront cash payment, fees to support technology transfer, and near-term milestone payments based on the program’s development progress. Read more >>